Options for drug-eluting stent (DES) manufacturers to differentiate their products include stent material, stent shape, drug-deposition methods and others, but most importantly the drug itself. The first drug employed in drug-eluting stents was sirolimus in J&J's CYPHER stent, followed by Boston Scientific with its paclitaxel-coated TAXUS stent.
Since then (2003), the options for drug coatings have proliferated as each new market entrant vies for a clinical advantage.
"Others" includes undisclosed drug on pericardium covered stent, undisclosed drug in polymer drug delivery system, “Drug Q”, AVI-5126 (CoCr), dexamethasone, dual drug (zotarolimus and dexamethasone), myolimus, novolimus, rapamycin with biodegradable polymer coating, tretinoin, Undisclosed antiproliferative, undisclosed drug (biodegradable, absorbable), and voclosporin.
Source: MedMarket Diligence report #C245, "Worldwide Market for Coronary Stents."
Posted via email from medmarket's posterous
bookmark to
Drug variations in drug-eluting stents
Comments 2
Interesting data on a competitive market.
Point to clarify in the data: Are Rapamycin and Sirolimus the same drug?
Keep up the great posts!
TrialDox team
Posted 02 Dec 2009 at 5:19 pm ¶http://blog.trialdox.com
@trialdox
Yes, you are right. We overlooked this. The graphic has been updated. Thanks for the catch!
Posted 02 Dec 2009 at 5:39 pm ¶Post a Comment